SecBot SecBot
PRESS-RELEASE ·Filed Aug 17, 2026

FULC

Fulcrum Therapeutics, Inc.; Slate Medicines
BULLISH
Impact 8/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

Fulcrum stockholders should evaluate whether to hold through the merger to receive the ~$270M cash dividend (estimated) plus 5% equity stub in SLTE, or sell into the likely premium. The $245M PIPE provides a strong validation signal for Slate's pipeline, but SLTE-1009 is still pre-Phase 1 data (mid-2027), the combined entity is a pre-revenue biotech with binary clinical risk. Monitor the S-4 filing for exact dividend amount and exchange ratio.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.84
T+0 close · Aug 17, 2026 · via day close
Latest settled
−3.13%
T+60 · $3.72
Vs SPY
−0.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 17 $3.84entry
  2. T+1 · 3mo ago +0.78%α +1.46% · $3.87
  3. T+5 · 3mo ago 0.00%α +1.19% · $3.84
  4. T+20 · 2mo ago −1.56%α +0.42% · $3.78
  5. T+60 · 7d ago −3.13%α −0.18% · $3.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fulcrum Therapeutics is being acquired by Slate Medicines in an all-stock reverse merger where pre-merger Fulcrum stockholders will own 5% of the combined company (subject to net cash adjustment) and receive an estimated $270M cash dividend immediately before closing. The combined entity will operate as Slate Medicines (ticker SLTE) and focus on Slate's migraine pipeline, including SLTE-1009, backed by a $245M oversubscribed private placement led by Frazier Life Sciences. For Fulcrum stockholders, this is effectively a liquidation event with a large cash dividend and a small ongoing equity stub in a pre-revenue biotech.

Key Financial Metrics

Deal Value
$270.0M

Key Facts

  • Pre-merger Fulcrum stockholders to own 5.0% of combined company (subject to net cash adjustment)
  • Fulcrum to pay estimated $270.0M cash dividend to pre-merger stockholders immediately before closing
  • Fulcrum contributes ~$20.3M net cash to combined entity
  • Slate secured $245M oversubscribed private placement led by Frazier Life Sciences
  • Combined company cash runway expected into 2029
  • Combined company to trade as SLTE on Nasdaq
  • Transaction expected to close in Q4 2026
  • Slate's lead asset SLTE-1009 is a clinical-stage anti-PACAP/VIP mAb for migraine prevention

Financial Impact

$270M cash dividend to Fulcrum stockholders (estimated) plus 5% equity stake in combined company valued at implied post-money of ~$5.1B based on $245M PIPE for 4.8%? Not calculable from filing alone. Fulcrum's ~$20.3M net cash contribution.

cash dividendownership dilutioncash runway

Risk Factors

  • Stockholder approval required from both companies, risk of vote failure
  • HSR antitrust waiting period and regulatory clearances needed
  • SLTE-1009 is pre-Phase 1 with no clinical data yet, binary pipeline risk
  • Fulcrum's 5% stub is tiny and illiquid post-merger
  • Dividend amount is an estimate subject to Fulcrum's net cash at closing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345962

Track record

23 reports on FULC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 17, 2026